

Optimize SIRT with The SIR-Spheres® Advantage

SIRTeX | SIR-Spheres®
Y-90 resin microspheres

ORDER-MAP-TREAT Programme



Intended Use / Indications For Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. **Warnings / Precautions:** Inadvertent delivery of the microspheres to locations other than the intended hepatic tumor may result in local radiation damage. Due to the radioactivity and the significant consequences of misplacing the microspheres in situ, this product must be implanted by physicians who have completed the Sirtex TEC training program. A SPECT scan of the upper abdomen immediately after implantation is recommended. Patients may experience abdominal pain immediately after administration and pain relief may be required. H-2 blocking agents may be administered the day before implantation and continued as needed to reduce gastric complications. **Side Effects:** Common side effects are fever, transient decrease of hemoglobin, mild to moderate abnormality of liver function tests, abdominal pain, nausea, vomiting, and diarrhea. Potential serious effects due to exposure to high radiation include acute pancreatitis, radiation pneumonitis, acute gastritis, radiation hepatitis, and acute cholecystitis. **Contraindications:** SIR-Spheres Y-90 resin microspheres should not be implanted in patients who have either had previous external beam radiation therapy to the liver, ascites or are in clinical liver failure. This device is contraindicated in patients with markedly abnormal synthetic and excretory liver function tests; greater than 20% lung shunting of the hepatic artery blood flow; disseminated extra-hepatic malignant disease, and portal vein thrombosis. This device should not be implanted in patients determined via angiogram to have an abnormal vascular anatomy that would result in significant reflux of the hepatic arterial blood flow to the stomach, pancreas, or bowel. General Information: SIR-Spheres Y-90 resin microspheres are radioactive and should thus be handled in accordance with all applicable standards and regulations.

Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.

SurePlan™ is a trademark of MIM Software Inc

Manufacturer

Sirtex Medical Pty Ltd
Shop 6, 207 Pacific Highway
St Leonards, NSW 2065
Australia
Tel: +61 2 9964 8400
Fax: +61 2 9964 8410

Europe, Middle East & Africa

Sirtex Medical Europe GmbH
Joseph-Schumpeter-Allee 33
53227 Bonn
Germany
Tel: +49 228 1840 730

www.sirtex.com

@SirtexMedical

company/sirtex-medical-limited

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
©2021 Sirtex Medical Europe GmbH

APM-EMEA-002-05-21-V2

SIRTeX



Empowering physicians to treat patients with expedited SIRT

Advancing to the next level.

ORDER-MAP-TREAT Programme



Treating your patients quickly, with confidence, is imperative to the patient, the referring physician, and the success of your Y-90 programme.

For the patient

- Reduced recovery time (Same-Day Map & Treat)
- Reduced time delays to treatment
- Fewer trips to hospital (Same-Day Map & Treat)

For the referring physician


- Improved treatment efficiencies
- Reduced interruptions between treatments
- Supports patient continuum of care

For the treating physician

- Unparalleled flexibility for interventional radiologists and nuclear medicine
- Personalised dose adjustments up to time of treatment

The **ORDER-MAP-TREAT Programme**, exclusive to resin Y-90, expedites SIRT delivery, utilizing the **SIR-Spheres Advantage**

Fast track from referral to treatment



MDT = Multidisciplinary Team / Tumor board

SIR-Spheres®
Y-90 resin microspheres